心血管领域的共同研究及授权契约:2016～2025年

本报告全面深入分析了全球领先的生物製药公司签署的心血管合作与许可协议，并提供前所未有的资讯取得管道。

本报告详细介绍了2016年至2025年间达成的589项心血管协议。

主要的优点

• 2016年以来的交易趋势
• 心血管合作与许可协议
• 透过基准分析确定市场价值
• 财务条款（预付款、里程碑付款、特许权使用费）
• 按公司、治疗领域和技术类型分类的合约目录
• 主要合约金额
• 最活跃的交易撮合者
• 查看每项协议的资产描述和条款
• 取得合约文件 - 深入了解合约结构
• 尽职调查 - 评估伙伴对建议条款的适用性
• 节省数百小时的研究时间

合约分析可协助您对以下内容进行尽职调查：

• 具体授予或选择哪些权利？
• 协议具体授予合作伙伴哪些权利？
• 授予哪些独家权利？
• 合约的付款结构是什么？
• 收入和付款将如何审计？
• 合约期限是多久？
• 合约的关键条款是如何定义的？
• 知识产权 (IPR) 将如何处理以及归谁所有？
• 谁负责商业化？
• 谁负责开发、供应和製造？
• 如何管理保密性和结果揭露？
• 争议将如何解决？
• 合约在什么情况下可以终止？
• 如果公司所有权发生变更，合约会如何处理？
• 关于转授权和分包，双方约定了哪些条款？
• 公司合约中通常包含哪些 "范本条款" ？
• 哪些 "范本条款" 会因合约当事人和合约类型而异？
• 公司要求以哪一法院作为契约法管辖地？

目录

摘要整理

第1章 简介

第2章 心血管领域的契约动向

• 各年度的联盟趋势
• 各交易类型的联盟趋势
• 各产业部门的联盟趋势
• 各开发阶段的联盟趋势
• 各技术类型的联盟趋势
• 各治疗适应症的联盟趋势

第3章 心臟血管领域的财务条件分析

• 明确指示的财务条件
• 契约总额
• 预付款金
• 里程金
• 权利金费率

第4章 心血管领域的主要交易商与契约

• 最活跃的契约企业
• 最活跃的交易商清单
• 契约金额前几名的契约

第5章 心血管领域:契约文件的名录

• 可取得的联盟契约文件

第6章 心血管领域的契约:治疗标的

• 依治疗标靶划分的心血管合约
• 合约目录
• 合约目录：依公司划分
• 合约目录：依技术类型划分
• 交易类型定义
• 关于 Biopharma Research Ltd
• 当前合作
• 当前协议
• 近期目前合作报告标题

Cardiovascular Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cardiovascular deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 589 cardiovascular deals from 2016 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cardiovascular dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in cardiovascular dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the cardiovascular field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in cardiovascular dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of cardiovascular deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of cardiovascular deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in cardiovascular deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cardiovascular Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse cardiovascular collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Cardiovascular Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cardiovascular trends and structure of deals entered into by leading biopharma companies worldwide.

Cardiovascular Collaboration and Licensing Deals includes:

• Trends in cardiovascular dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of cardiovascular deal records covering pharmaceutical and biotechnology
• The leading cardiovascular deals by value
• Most active cardiovascular licensing dealmakers

In Cardiovascular Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Cardiovascular Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cardiovascular dealmaking

• 2.1. Introduction
• 2.2. Cardiovascular partnering over the years
• 2.3. Cardiovascular partnering by deal type
• 2.4. Cardiovascular partnering by industry sector
• 2.5. Cardiovascular partnering by stage of development
• 2.6. Cardiovascular partnering by technology type
• 2.7. Cardiovascular partnering by therapeutic indication

Chapter 3 - Financial deal terms for cardiovascular partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for cardiovascular partnering
• 3.3. Cardiovascular partnering headline values
• 3.4. Cardiovascular deal upfront payments
• 3.5. Cardiovascular deal milestone payments
• 3.6. Cardiovascular royalty rates

Chapter 4 - Leading cardiovascular deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in cardiovascular partnering
• 4.3. List of most active dealmakers in cardiovascular
• 4.4. Top cardiovascular deals by value

Chapter 5 - Cardiovascular contract document directory

• 5.1. Introduction
• 5.2. Cardiovascular partnering deals where contract document available

Chapter 6 - Cardiovascular dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by cardiovascular therapeutic target
• Deal directory
• Deal directory - Cardiovascular deals by company A-Z 2016 to 2025
• Deal directory - Cardiovascular deals by technology type 2016 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Cardiovascular partnering since 2016
• Figure 2: Cardiovascular partnering by deal type since 2016
• Figure 3: Cardiovascular partnering by industry sector since 2016
• Figure 4: Cardiovascular partnering by stage of development since 2016
• Figure 5: Cardiovascular partnering by technology type since 2016
• Figure 6: Cardiovascular partnering by indication since 2016
• Figure 7: Cardiovascular deals with a headline value
• Figure 8: Cardiovascular deals with upfront payment values
• Figure 9: Cardiovascular deals with milestone payment
• Figure 10: Cardiovascular deals with royalty rates
• Figure 11: Active cardiovascular dealmaking activity since 2016
• Figure 12: Top cardiovascular deals by value since 2016